Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Luis Peña Icart, Fernando Gomes de Souza$suffix/text()$suffix/text() & Luís Maurício T. R. Lima. (2019) Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles. Journal of Microencapsulation 36:8, pages 747-758.
Read now
Read now
Filip K. Knop, Andreas Brønden & Tina Vilsbøll. (2017) Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opinion on Pharmacotherapy 18:6, pages 555-571.
Read now
Read now
Katherine V Mann & Philip Raskin. (2014) Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 7, pages 229-239.
Read now
Read now
Courtney Aavang Tibble, Tricia Santos Cavaiola & Robert R Henry. (2013) Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Review of Endocrinology & Metabolism 8:3, pages 247-259.
Read now
Read now
Articles from other publishers (17)
T.D. Müller, B. Finan, S.R. Bloom, D. D'Alessio, D.J. Drucker, P.R. Flatt, A. Fritsche, F. Gribble, H.J. Grill, J.F. Habener, J.J. Holst, W. Langhans, J.J. Meier, M.A. Nauck, D. Perez-Tilve, A. Pocai, F. Reimann, D.A. Sandoval, T.W. Schwartz, R.J. Seeley, K. Stemmer, M. Tang-Christensen, S.C. Woods, R.D. DiMarchi & M.H. Tschöp. (2019) Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 30, pages 72-130.
Crossref
Crossref
Hsin-Jung Ho, Hitoshi Shirakawa, Keisukei Hirahara, Hideyuki Sone, Shin Kamiyama & Michio Komai. (2019) Menaquinone-4 Amplified Glucose-Stimulated Insulin Secretion in Isolated Mouse Pancreatic Islets and INS-1 Rat Insulinoma Cells. International Journal of Molecular Sciences 20:8, pages 1995.
Crossref
Crossref
Sohee Son, Eun Ji Park, Yejin Kim, Kang Choon Lee & Dong Hee Na. (2018) Chemical chaperone-conjugated exendin-4 as a cytoprotective agent for pancreatic β-cells. The International Journal of Biochemistry & Cell Biology 105, pages 13-19.
Crossref
Crossref
Dimitrios Sfairopoulos, Stavros Liatis, Stelios Tigas & Evangelos Liberopoulos. (2018) Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones 17:3, pages 333-350.
Crossref
Crossref
Sergei Pechenov, Himanshu Bhattacharjee, Daniel Yin, Sachin Mittal & J. Anand Subramony. (2017) Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Advanced Drug Delivery Reviews 112, pages 106-122.
Crossref
Crossref
Susan L. Samson & Alan J. Garber. (2016) A Plethora of GLP-1 Agonists: Decisions About What to Use and When. Current Diabetes Reports 16:12.
Crossref
Crossref
M. Odawara, J. Miyagawa, N. Iwamoto, Y. Takita, T. Imaoka & T. Takamura. (2016)
Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in
J
apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase
III
study
. Diabetes, Obesity and Metabolism 18:3, pages 249-257.
Crossref
Crossref
Regin Elsa George & Siby Joseph. (2014) A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal 22:5, pages 403-410.
Crossref
Crossref
Hale M. Tasyurek, Hasan Ali Altunbas, Mustafa Kemal Balci & Salih Sanlioglu. (2014) Incretins: Their physiology and application in the treatment of diabetes mellitus. Diabetes/Metabolism Research and Reviews 30:5, pages 354-371.
Crossref
Crossref
Zachary L. Anderson & Jennifer N. Clements. (2014) Exenatide extended-release. Journal of the American Academy of Physician Assistants 27:6, pages 44-46.
Crossref
Crossref
Jeffrey S. Freeman. (2013) Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies. Osteopathic Family Physician 5:1, pages 43-50.
Crossref
Crossref
Christine Beeton. 2013. Handbook of Biologically Active Peptides. Handbook of Biologically Active Peptides
473
482
.
T. Ridge, T. Moretto, L. MacConell, R. Pencek, J. Han, C. Schulteis & L. Porter. (2012)
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily)
GLP
‐1 receptor agonism in patients with type 2 diabetes
. Diabetes, Obesity and Metabolism 14:12, pages 1097-1103.
Crossref
Crossref
Krystal L. EdwardsMegan StapletonJessica WeisBrian K. Irons. (2012) An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Technology & Therapeutics 14:10, pages 951-967.
Crossref
Crossref
Susan LaRue, Mary Beth DeYoung, Amy Blickensderfer & Steve Chen. (2012) Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes. Clinical Diabetes 30:3, pages 95-100.
Crossref
Crossref
Lisa S. Rotenstein, Benjamin M. Kozak, Joseph P. Shivers, Mark Yarchoan, John Close & Kelly L. Close. (2012) The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?. Clinical Diabetes 30:2, pages 44-53.
Crossref
Crossref
Dhanwantee Mundil, Alison Cameron-Vendrig & Mansoor Husain. (2012) GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. Diabetes and Vascular Disease Research 9:2, pages 95-108.
Crossref
Crossref